Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis
- PMID: 30253783
- PMCID: PMC6157064
- DOI: 10.1186/s13014-018-1136-5
Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis
Abstract
Background: There is currently no worldwide consensus for the management of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). We evaluated the efficacy of stereotactic body radiotherapy (SBRT) as the initial treatment for HCC with extensive PVTT based on a relatively large number of patients.
Methods: In our multidisciplinary approach for patients with hepatobiliary tumors, SBRT is recommended for unresectable HCC with PVTT or those with contraindication for transarterial chemoembolization (TACE). The aim is to shrink the tumor thrombus and preserve adequate portal venous flow, thus facilitating subsequent treatments such as TACE and tumor resection. In the present study, 70 continuous cases of HCC patients with extensive PVTT initially treated with SBRT were studied. The median follow-up period was 9.5 months (range, 1.0-21.0 months). The dynamic changes of tumor thrombosis with time after SBRT were also analyzed.
Results: The median survival time for the whole group was 10.0 months (95% CI, 7.7-12.3 months), with a 6- and 12-month overall survival (OS) rate of 67.3%, and 40.0% respectively. Patients who received combined SBRT and TACE showed significantly longer OS than those without indication for TACE after SBRT (12.0 ± 1.6 vs. 3.0 ± 1.0 months). Patients with good response to radiation usually had better survival. SBRT was well tolerated in our patient series.
Conclusions: In conclusion, SBRT used as the initial treatment for HCC patients with extensive PVTT originally unsuitable for resection or TACE can achieve adequate thrombus shrinkage and portal vein flow restoration in the majority of cases. It could thus offer the patients an opportunity to undergo further treatment such as resection or TACE procedure. Such therapeutic strategy may result in survival advantage, especially for those who do receive combined modality with SBRT.
Keywords: Hepatocellular carcinoma; Portal vein tumor thrombosis; Stereotactic body radiotherapy; Transarterial chemoembolization.
Conflict of interest statement
Ethics approval and consent to participate
This study was approved by the Ethics Committee of SAHZU, and was carried out in accordance with the Declaration of Helsinki.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044767 Free PMC article.
-
Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.Asia Pac J Clin Oncol. 2021 Jun;17(3):209-215. doi: 10.1111/ajco.13361. Epub 2020 Aug 5. Asia Pac J Clin Oncol. 2021. PMID: 32757461
-
Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.BMC Cancer. 2021 Jun 15;21(1):701. doi: 10.1186/s12885-021-08469-1. BMC Cancer. 2021. PMID: 34126955 Free PMC article.
-
Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?Int J Radiat Biol. 2022;98(10):1495-1509. doi: 10.1080/09553002.2022.2055800. Epub 2022 Apr 4. Int J Radiat Biol. 2022. PMID: 35311612 Review.
-
Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.BMC Cancer. 2017 Dec 28;17(1):902. doi: 10.1186/s12885-017-3895-z. BMC Cancer. 2017. PMID: 29282010 Free PMC article. Review.
Cited by
-
Liver transplantation for hepatocellular carcinoma in India: Are we ready for 2040?World J Transplant. 2024 Mar 18;14(1):88833. doi: 10.5500/wjt.v14.i1.88833. World J Transplant. 2024. PMID: 38576752 Free PMC article.
-
Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape.Cancers (Basel). 2024 Feb 4;16(3):666. doi: 10.3390/cancers16030666. Cancers (Basel). 2024. PMID: 38339417 Free PMC article. Review.
-
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma.Front Oncol. 2023 Jul 24;13:1193762. doi: 10.3389/fonc.2023.1193762. eCollection 2023. Front Oncol. 2023. PMID: 37554167 Free PMC article. Review.
-
An observational study on tumour response of portal vein tumour thrombus in hepatocellular carcinoma.J Radiosurg SBRT. 2022;8(4):257-264. J Radiosurg SBRT. 2022. PMID: 37416331 Free PMC article.
-
Chemotherapy combined with radiotherapy can benefit more unresectable HCC patients with portal and/or hepatic vein invasion: a retrospective analysis of the SEER database.Front Oncol. 2023 Jun 20;13:1098686. doi: 10.3389/fonc.2023.1098686. eCollection 2023. Front Oncol. 2023. PMID: 37409255 Free PMC article.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous